Edition:
United States

CRISPR Therapeutics AG (CRSP.OQ)

CRSP.OQ on NASDAQ Stock Exchange Global Market

17.89USD
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
$17.89
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
64,087
52-wk High
$24.85
52-wk Low
$11.74

Latest Key Developments (Source: Significant Developments)

Vertex, CRISPR Therapeutics To Co-Develop CTX001 As CRISPR/Cas9 Gene Edited Treatment
Tuesday, 12 Dec 2017 08:30am EST 

Dec 12 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX AND CRISPR THERAPEUTICS TO CO-DEVELOP AND CO-COMMERCIALIZE CTX001 AS CRISPR/CAS9 GENE EDITED TREATMENT FOR SICKLE CELL DISEASE AND Β-THALASSEMIA.VERTEX PHARMACEUTICALS INC - VERTEX SELECTS CTX001 AS FIRST GENE EDITED TREATMENT TO BE DEVELOPED AS PART OF COLLABORATION WITH CRISPR THERAPEUTICS.VERTEX PHARMACEUTICALS - TRIAL APPLICATION FOR CTX001 SUBMITTED IN EUROPE TO SUPPORT INITIATION OF PHASE 1/2 CLINICAL STUDY IN Β-THALASSEMIA IN 2018.VERTEX PHARMACEUTICALS - IND APPLICATION PLANNED FOR SUBMISSION IN 2018 TO SUPPORT INITIATION OF A PHASE 1/2 TRIAL IN SICKLE CELL DISEASE FOR CTX001.  Full Article

CRISPR Therapeutics Submits First Clinical Trial Application For CRISPR Gene-Edited Therapy, In Β-Thalassemia
Thursday, 7 Dec 2017 07:00am EST 

Dec 7 (Reuters) - Crispr Therapeutics Ag ::CRISPR THERAPEUTICS SUBMITS FIRST CLINICAL TRIAL APPLICATION FOR A CRISPR GENE-EDITED THERAPY, CTX001 IN Β-THALASSEMIA.CRISPR THERAPEUTICS AG - ANNOUNCED SUBMISSION OF A CLINICAL TRIAL APPLICATION FOR CTX001 IN Β-THALASSEMIA.CRISPR THERAPEUTICS AG - PHASE 1/2 TRIAL OF CTX001 IS EXPECTED TO BEGIN IN EUROPE IN 2018.CRISPR THERAPEUTICS AG - CO ALSO PLANS TO FILE AN INVESTIGATIONAL NEW DRUG APPLICATION FOR CTX001 TO TREAT SICKLE CELL DISEASE WITH U.S. FDA IN 2018.  Full Article

CRISPR and Casebia collaborate with CureVac on mRNA for gene-editing programs
Monday, 13 Nov 2017 05:00am EST 

Nov 13 (Reuters) - CRISPR Therapeutics AG :CRISPR Therapeutics and Casebia collaborate with CureVac on mRNA for gene-editing programs.‍Under terms, CureVac will develop novel Cas9 mRNA constructs with improved properties for gene editing applications​.‍In exchange, CureVac will receive an upfront payment and research funding ​.CRISPR Therapeutics-‍CureVac to also be eligible to receive development, commercial milestones, royalties on commercialized products from collaboration​.  Full Article

Crispr Therapeutics files for mixed shelf offering of up to $300 mln - SEC filing‍​
Thursday, 9 Nov 2017 05:33pm EST 

Nov 9 (Reuters) - Crispr Therapeutics AG :Crispr Therapeutics AG - files for mixed shelf offering of up to $300 million - SEC filing‍​.  Full Article

CRISPR Therapeutics announces third quarter results
Wednesday, 8 Nov 2017 04:05pm EST 

Nov 8 (Reuters) - CRISPR Therapeutics AG :CRISPR Therapeutics announces third quarter 2017 financial results and provides business update.CRISPR Therapeutics ag qtrly net ‍loss per share attributable to common shareholders​ of $0.62.  Full Article

CRISPR Therapeutics promotes Samarth Kulkarni to CEO
Monday, 2 Oct 2017 07:30am EDT 

Oct 2 (Reuters) - Crispr Therapeutics Ag :CRISPR Therapeutics announces promotion of Samarth Kulkarni, Ph.D. to chief executive officer.CRISPR Therapeutics - ‍rodger Novak, co-founder and current CEO, is stepping down from his current role for personal reasons​.CRISPR Therapeutics - Rodger Novak to continue to serve as member of co's board and as an officer of its Swiss parent company, CRISPR AG​.  Full Article

Crispr Therapeutics Ag qtrly ‍net loss per share attributable to common shareholders $0.56​
Thursday, 10 Aug 2017 04:35pm EDT 

Aug 10 (Reuters) - Crispr Therapeutics Ag :Crispr Therapeutics announces second quarter 2017 financial results and provides business update.Crispr Therapeutics Ag - ‍as of June 30, 2017, Crispr Therapeutics had $272.3 million in cash as compared to $315.5 million in cash as of December 31, 2016​.Crispr Therapeutics Ag qtrly ‍net loss per share attributable to common shareholders $0.56​.Crispr Therapeutics Ag - ‍lead hemoglobinopathies program remains on track to file CTA by year-end 2017, and begin clinical trials in 2018​.Crispr Therapeutics Ag - ‍remains on track to file a clinical trial application (CTA) in Europe by year-end 2017 for beta-thalassemia​.  Full Article

Crispr Therapeutics AG says Marc Becker will not resume his duties as CFO
Thursday, 27 Jul 2017 06:45am EDT 

July 27 (Reuters) - Crispr Therapeutics AG ::Says Marc Becker will not resume his duties as CFO.Crispr Therapeutics AG - CFO Marc Becker will be leaving his functions at co as of Sept. 30, 2017 .Says board of directors has begun search for company's next Chief Financial Officer.Becker had been on family and medical leave, as disclosed in march.  Full Article

Crispr Therapeutics, Neon Therapeutics enter research collaboration​
Monday, 10 Jul 2017 08:30am EDT 

July 10 (Reuters) - Crispr Therapeutics Ag :Crispr Therapeutics AG - ‍co, Neon Therapeutics enter research collaboration​.Crispr Therapeutics - ‍announced research collaboration to explore combination of each co's proprietary technologies to develop Novel T Cell therapies​.  Full Article

CRISPR Therapeutics announces patent for CRISPR/CAS genome editing in china
Monday, 19 Jun 2017 07:30am EDT 

June 19 (Reuters) - CRISPR Therapeutics AG ::CRISPR Therapeutics announces patent for CRISPR/CAS genome editing in China.CRISPR Therapeutics AG - China's state intellectual property office granted a patent broadly covering CRISPR's in-licensed gene editing technology.  Full Article

BRIEF-Vertex, CRISPR Therapeutics To Co-Develop CTX001 As CRISPR/Cas9 Gene Edited Treatment

* VERTEX AND CRISPR THERAPEUTICS TO CO-DEVELOP AND CO-COMMERCIALIZE CTX001 AS CRISPR/CAS9 GENE EDITED TREATMENT FOR SICKLE CELL DISEASE AND Β-THALASSEMIA